MolDX has proposed a draft Local Coverage Determination to establish Medicare coverage criteria for optical genome mapping in hematologic neoplasms, with public comment open through Oct. 11, 2026, according to Bionano Laboratories.
Pillar Biosciences, LC-SCRUM-Asia, and LSI Medience will collaborate on a two-year, 2,000-patient liquid biopsy lung cancer screening project in Japan, using cfDNA and cfRNA testing.
Concert has issued a coverage policy deeming the EsoGuard Esophageal DNA Test medically necessary for eligible patients, with multiple client health plans now adopting the policy.
10x Genomics and Lausanne University Hospital have begun a multi-year study using single cell and spatial technologies to identify biomarkers predicting treatment response in patients with advanced solid tumors.
Read More
Alveo Technologies and UTMB have partnered to develop point-of-care diagnostics for Lassa fever, deploying molecular sensing platforms at clinical sites in Nigeria and Sierra Leone to support real-time pathogen detection.
Read More
HerAnova Lifesciences reported real-world data on its HerResolve multi-omic blood test for endometriosis at the 2026 Midwest Reproductive Annual Symposium, showing consistent performance across 197 cases in diverse clinical settings.
Read More
OnsiteGene has unveiled myNAT, a handheld, battery-powered real-time PCR instrument capable of 40-cycle runs in under 10 minutes, with a target cost of under $5 per test, according to the company.
Read More
RNA-based testing improves detection of MET exon 14 skipping in NSCLC, identifying mutations missed by DNA-only assays, according to new research. Findings may impact eligibility for targeted therapies.
Read More
Seegene has introduced a syndromic PCR-based test for simultaneous detection of STIs and HPV. Company data show co-detection in 71% of positive cases, supporting potential clinical utility for comprehensive reproductive infection screening.
Read More
Labcorp has announced the upcoming launch of the Marker by Labcorp Genetic Health Panel, which will analyze 163 genes linked to over 100 medically actionable conditions, with results supported by licensed genetic counselors.
Read More
The company is showcasing newly cleared tests and platforms for multiple myeloma, lung cancer, connective tissue disease, and other laboratory applications.
Read More
The funding will support regulatory certification and the commercial launch of rapid tests for Lyme disease and sexually transmitted infections.
Read More
As Cyclospora infections surge in the US, laboratories face increased pressure to quickly differentiate cases, with the CDC reporting 1,947 confirmed infections and 98 hospitalizations across nine states as of July 24.
Read More
The program connects researchers with certified laboratories offering single-molecule PCR testing, technical support, and bioinformatics expertise.
Read More
The test uses intact circulating tumor cells instead of cell-free DNA fragments to analyze more than 500 genes and identify tumor markers.
Read More
Cepheid will debut its third-generation GeneXpert molecular testing system at ADLM 2024, featuring a touchscreen interface, updated software, and continued support for FDA-cleared tests and existing laboratory workflows.
Read More
Myriad Genetics has launched the FirstGene Multiple Prenatal Screen, a test that combines four prenatal genetic screens from a single blood draw as early as eight weeks gestation, according to the company.
Read More
Seegene has launched the Global Million Clinical Study to collect real-world data on the clinical utility of syndromic PCR testing for infectious diseases, aiming to inform future global diagnostic standards.
Read More